Literature DB >> 8032579

Pharmacokinetics of phenprocoumon.

K O Haustein1, G Hüller.   

Abstract

The pharmacokinetics of phenprocoumon was studied in 24 healthy volunteers between the ages of 23 and 28 years and a mean body weight of 72 kg by intraindividual comparison of the plasma level after i.v. and oral administration of 9 mg phenprocoumon (PPC) or by the evaluation of the total plasma clearance of PPC by simultaneous measurement of the urinary excretion and of the plasma concentration after the administration of 9 mg PPC. The following mean data were obtained after i.v. injection:t1/2 alpha 0.432h, t1/2 beta 128 h, co 0.651 microgram/ml, Vd 14.41,AUCo-omega 121 micrograms x h/ml. After intake of 9 mg PPC the following mean values were measured: tmax 2.25 h, Cmax 1.01 micrograms/ml, tabs 0.553 h, co 0.865 micrograms/ml, t1/2 beta 132 h, AUC0-infinity 164 micrograms x h/ml. By comparison of the PPC plasma level with the corresponding urinary excretion, a total mean PPC clearance of 20.0 (i.v.) and 15.1 (per os) ml/h was calculated within the first 8 h post dose, while the values measured did not differ between 8 and 48 h post dose (14.8 vs 15.3 ml/h). The steep decline in plasma level after i.v. injection of PPC might be caused by an enhanced renal and hepatic elimination of the free drug to a higher degree than after oral intake, while no differences existed between both modes of administration during the phase of elimination. A nearly total absorption of PPC from the tablet formulation is suggested.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032579

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  7 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

3.  Thrombosis of A Prosthetic Mitral Valve After Withdrawal of Phenprocoumon Therapy.

Authors:  Andreas Wilke; Christian M Wende; Michael Horst; Dietmar Steverding
Journal:  Cardiol Res       Date:  2011-11-20

4.  Spontaneous and non-spontaneous bleeding complications in patients with oral vitamin K antagonist therapy.

Authors:  Martin Hoffmann; Markus Zimmermann; Rüdiger Meyer; Tilman Laubert; Nehara Begum; Tobias Keck; Peter Kujath; Erik Schloericke
Journal:  Langenbecks Arch Surg       Date:  2013-12-05       Impact factor: 3.445

5.  Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.

Authors:  Khaled Abduljalil; Simone Lazar; Michael Natanzon; Weidong Wu; Gregor Zadoyan; Benedict Steffens; Victoria Kohl; Klaus Mörike; Dorota Tomalik-Scharte; Julia Stingl; Matthias Schwab; Job Harenberg; Christoph Gleiter; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

Review 6.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

7.  Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine.

Authors:  Sophie N B Selby-Pham; Rosalind B Miller; Kate Howell; Frank Dunshea; Louise E Bennett
Journal:  Sci Rep       Date:  2017-05-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.